NO20083895L - Anti-IGF-1R human monoclonal antibody formulation - Google Patents

Anti-IGF-1R human monoclonal antibody formulation

Info

Publication number
NO20083895L
NO20083895L NO20083895A NO20083895A NO20083895L NO 20083895 L NO20083895 L NO 20083895L NO 20083895 A NO20083895 A NO 20083895A NO 20083895 A NO20083895 A NO 20083895A NO 20083895 L NO20083895 L NO 20083895L
Authority
NO
Norway
Prior art keywords
igf
human monoclonal
monoclonal antibody
antibody formulation
formulation
Prior art date
Application number
NO20083895A
Other languages
Norwegian (no)
Inventor
Adelbert Grossmann
Jan Stracke
Hanns-Christian Mahler
Astrid Pappenberger
Oliver Boris Stauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20083895L publication Critical patent/NO20083895L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

Sammendrag Foreliggende oppfinnelse angår en humant monoklonalt anti-IGF-1R-antistoff-formulering, fremgangsmåte for fremstilling derav og anvendelse derav. 270 29SUMMARY OF THE INVENTION The present invention relates to a human monoclonal anti-IGF-1R antibody formulation, process for its preparation and use. 270 29

NO20083895A 2006-03-28 2008-09-11 Anti-IGF-1R human monoclonal antibody formulation NO20083895L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28
PCT/EP2007/052569 WO2007110339A1 (en) 2006-03-28 2007-03-19 Anti-igf-1r human monoclonal antibody formulation

Publications (1)

Publication Number Publication Date
NO20083895L true NO20083895L (en) 2008-10-24

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083895A NO20083895L (en) 2006-03-28 2008-09-11 Anti-IGF-1R human monoclonal antibody formulation

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006199A (en) * 2006-12-11 2009-06-22 Hoffmann La Roche Abeta antibody parenteral formulation.
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
US20100260766A1 (en) * 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
WO2009007272A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
WO2009068282A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
UA101487C2 (en) * 2007-12-21 2013-04-10 Ф. Хоффманн-Ля Рош Аг Humanized b-ly1 antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
KR20120110175A (en) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 Antibody formulation
KR20130086144A (en) * 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 Stable multi-dose compositions comprising an antibody and a preservative
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
JP6707469B2 (en) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド Lyophilized formulation of Tat-NR2B9c containing acetylated scavenger
TW201628649A (en) 2014-10-09 2016-08-16 再生元醫藥公司 Process for reducing subvisible particles in a pharmaceutical formulation
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
CN106999591B (en) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 anti-PD-1 antibody preparation and application thereof in medicine
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
KR102511050B1 (en) 2016-08-16 2023-03-17 리제너론 파아마슈티컬스, 인크. Methods for quantitating individual antibodies from a mixture
PL3532838T3 (en) 2016-10-25 2022-10-03 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
RU2019138507A (en) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TW202005694A (en) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
PE20020801A1 (en) * 2001-01-05 2002-09-06 Pfizer ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR RECEPTOR
JP4317010B2 (en) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド Stable lyophilized pharmaceutical formulation of IgG antibody
EP1613658B1 (en) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
AR046071A1 (en) * 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
AU2004265152A1 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human IGF-1R antibodies

Also Published As

Publication number Publication date
RU2008142359A (en) 2010-05-10
ECSP088778A (en) 2008-10-31
KR20080104160A (en) 2008-12-01
CL2007000797A1 (en) 2008-01-25
EP1998806A1 (en) 2008-12-10
TW200815029A (en) 2008-04-01
AR060130A1 (en) 2008-05-28
WO2007110339A1 (en) 2007-10-04
IL193904A0 (en) 2011-08-01
MA30345B1 (en) 2009-04-01
CA2647111A1 (en) 2007-10-04
BRPI0709229A2 (en) 2011-06-28
CN101410137A (en) 2009-04-15
MX2008012295A (en) 2008-10-09
JP2009531371A (en) 2009-09-03
CR10295A (en) 2008-10-06
AU2007229554A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
NO20083895L (en) Anti-IGF-1R human monoclonal antibody formulation
CY2018013I1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CY1115932T1 (en) ANTIBODY PACKAGING
NO20081124L (en) Anti-CD 3 antibody formulations
CY1117563T1 (en) HER3 PARTS AND USE OF THESE
CY1117331T1 (en) ACCESSORIES IN ACCESSIBILITY 4 OUTSIDE AUTOMATIC CSF1R AND THEIR USE
NO20170633A1 (en) Compounds of indolamine-2,3-dioxygenase for use in the treatment of cancer in combination with an anti-PD-1 antibody.
CY1117124T1 (en) HUMANIZED ANTI-β7 ANTAGONISTS AND THEIR USES
CY1116261T1 (en) ANTIBODIES AND IMMUNITIES AND THEIR USES
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
CY1111729T1 (en) BALANCED COVERED TABLET
CY1114926T1 (en) ANTIBODIES AND IMMUNITIES AND USES OF THESE
NO20083891L (en) Anti-5T4 antibodies and uses thereof
DOP2009000269A (en) HUMANIZED ANTIBODIES AGAINST GLOBULOMERO AB (20-42) AND ITS USES
NO20074238L (en) Fixed dosage of HER antibodies
EA201100694A1 (en) ANTIBODY TO CD38 PERSON AND ITS APPLICATION
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
TW200716646A (en) (S)-N-methylnaltrexone
NO20076687L (en) Oral dosage form
CY1109916T1 (en) Benzimidazolo-thiophene compounds as PLK inhibitors
NO20083593L (en) Anti-EphrinB2 antibodies and methods for their use
EA200970816A1 (en) NEW MEDICINE FORM
MX2013002718A (en) Anti-vegfr-3 antibody compositions.
NO20091386L (en) Fenyloksyanilinderivater
UA96426C2 (en) Isolated human or humanized antibody that specifically binds to il-13

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application